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because of toxicity (hypertension, proteinuria, and fatigue) and in two 
patients because of disease progression. Ktrans was not associated with 
tumor response whilst blood ﬂow and permeability-surface area prod-
uct (derived from distributed parameters model) was associated with 
tumor response in two patients.
Conclusion: continuous dosing of ABT-869 is tolerable with activity 
seen in patients with NSCLC. Early evidence of reduced tumor ﬂow 
and capillary permeability was observed on DCE MRI. ABT-869 has 
promising activity in NSCLC and is currently being investigated in a 
phase II study. 
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Background: Vorinostat (Zolinza™) is a histone deacetylase inhibi-
tor shown to inhibit growth and induce differentiation and apoptosis 
in preclinical cancer models. Vorinostat has also demonstrated clinical 
activity in patients with various hematologic and solid tumors including 
cutaneous T-cell lymphoma.
Methods: In this Phase I trial, Japanese patients with solid tumors who 
had failed standard therapy were enrolled at the National Cancer Center 
Hospital. Patients received vorinostat BID for 14 consecutive days 
followed by a 7 day-rest. The initial dose was 100 mg BID and was 
escalated by 100 mg BID until the maximum tolerated dose (MTD) 
was established. Once daily dosing was subsequently tested at 400 
and 500 mg. Pharmacokinetics (PK) were measured, and response was 
evaluated according to the International Workshop Criteria.
Results: The MTD was established as 200 mg BID and 500 mg QD for 
14 consecutive days followed by a 7 day-rest. All 18 enrolled patients 
were assessed for safety and PK. The median age was 58 years (range, 
25-72). Ten of 18 patients had lung cancer. Dose limiting toxicities 
(DLTs) were observed in 2 of 6 patients receiving 200 mg BID: Grade 
4 thrombocytopenia, and Grade 4 thrombocytopenia and Grade 3 an-
orexia. There were no DLTs in the 3 patients receiving 400 mg QD. At 
500 mg QD, 1 of 6 patients experienced Grade 3 anorexia and fatigue. 
Over the 100 to 500 mg dose range, vorinostat AUC increased gener-
ally in proportion to dose. PK was not greatly impacted by multiple 
doses. Excretion of intact drug in the urine was <1% of the dose. The 
PK proﬁle is similar to that established in US patients. As of December 
2006, 1 patient with invasive thymoma had received 200 mg BID for 1 
year and nine patients have achieved stable disease as best response.
Conclusions: Vorinostat 200 mg BID or 500 mg QD for 14 consecu-
tive days followed by a 7 day-rest were safe and would be the recom-
mended doses on this schedule for Phase II trials.
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Background: The epidermal growth factor receptor (EGFR) is highly 
expressed in a signiﬁcant percentage of human malignancies and its 
expression is associated with tumor aggressiveness and treatment resis-
tance. The monoclonal antibody Cetuximab (C225) blocks the ligand 
binding domain of EGFR with high afﬁnity, preventing downstream 
signaling which results in tumor growth inhibition. Consequently, 
Cetuximab has evolved as a promising new targeted agent in oncology 
and is nowadays increasingly used in clinical trials in combination with 
chemo- / radiotherapy. Image modalities to monitor the binding of Ce-
tuximab non-invasively in cancer patients could signiﬁcantly increase 
our knowledge of the clinical use of Cetuximab as a targeted agent. To 
contribute to this knowledge, we developed and validated a new imag-
ing probe using Cetuximab labeled with the PET isotope Zirconium-89.
Methods: Human A431 epidermoid carcinoma cells were used as 
high EGFR expressing cells, glioblastoma U373 MG and colorectal 
adenocarcinoma HT29 cells as intermediate EGFR expressing cells, 
and T47D breast carcinoma cells as negative control. The in vitro 
expression of EGFR was assessed using Western blotting. Quantitative 
validation of speciﬁc binding of Cetuximab was done using ﬂuores-
cence-activated cell sorting (FACS) after incubation with Oregon 
Green 488 labeled Cetuximab. The in vivo binding of Cetuximab to 
EGFR was assessed by performing PET imaging from 0 to 96 hours 
on A431 and T47D tumor bearing NMRI-nu mice after injection of 
Zirconium-89 (89Zr) - labeled Cetuximab. Immunohistochemistry was 
used to validate the in vivo ﬁndings.
Results: Stability of Oregon Green 488 and 89Zr-labeled Cetuximab 
was conﬁrmed by MALDI-TOF and HPLC respectively. Gammacount-
ing of the 89Zr-cetuximab HPLC fractions demonstrated a radiochemi-
cal purity of 98%. Western blot analysis conﬁrmed EGFR expression 
in the corresponding cell lines. Speciﬁc binding of Oregon Green 488 
labeled Cetuximab was seen in EGFR expressing cell lines at a nano-
Molar saturation concentration. 
In mice, PET images showed clear delineation of EGFR-positive xe-
nografts, but not of EGFR-negative xenografts. Tumor-to-blood ratios 
in the EGFR expressing cell line were signiﬁcantly higher (P < 0.0015) 
compared to the negative control starting from 24 hours post injec-
tion, and reached an optimum after 72 hours due to the long biologic 
half-life of Cetuximab in the blood. Histopathology using anti-EGFR 
monoclonal antibodies conﬁrmed the ﬁndings seen non-invasively.
Conclusions: Using the newly developed probes, we assessed the bind-
ing of Cetuximab to EGFR both in vitro and in vivo. The 89Zr-cetux-
imab in vivo probe represents a promising tool to evaluate the biologic 
and pharmacokinetic effects of Cetuximab non-invasively. Monitoring 
these effects in combination with radiotherapy before, during and after 
treatment will ultimately result in individualized patient treatment. A 
phase I trial in patients is underway.
